Cancer Res (2022) 82 (12_Supplement): 3595. Combination treatment with RMC-6291 and SHP2 or SOS1 inhibitors was well tolerated in preclinical models and further increased anti-tumor activity, likely ...

Abstract:. Researchers utilized a two-vector system, consisting of an enveloped delivery vehicle and an adeno-associated virus to deliver CRISPR tools and a large DNA payload, to achieve stable and ...

De novo pyrimidine synthesis is a universal requirement for cancer cell proliferation; however, targeting this pathway results in toxicity to all dividing cells. The rate limiting conversion of UTP to ...

Abstract. Lung cancer is the leading cause of cancer death worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all lung cancers. At the time of diagnosis, it is ...

Cancer Epidemiol Biomarkers Prev (2009) 18 (6): 1740–1745. The U.S. active-duty military population may differ from the U.S. general population in its exposure to cancer risk factors and access to ...

*Corresponding Author: Sandra J. Casak, Office of Oncology Drugs, CDER, U.S. Food and Drug Administration, WO22 Room 2200, 10903 New Hampshire Avenue, Silver Spring ...

You do not currently have access to this content.

Supplementary Figure 1. Hierarchical clustering of response to single agent treatments.

1Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China.

Abstract. Monomethyl auristatin E (MMAE), the payload delivered by vedotin ADCs, exerts its cytotoxic effects via microtubule disruption and induction of ER stress, leading to apoptosis and tumor cell ...